G-CSF mobilized PBSCs are increasingly used in allo-SCT due to their relative ease of collection 1 and because higher CD34 þ cell doses may be associated with improved transplant outcomes in some settings.
. As per the institutional policy, the targeted total number of CD34 þ stem cells was between 4 and 8 Â 10 6 /kg recipient body weight to be collected in a maximum of three consecutive aphaeresis sessions while continuing G-CSF administration. Assessments were based on recipient body weight.
Overall, the median number of the total collected CD34 þ cells was 6.25 Â 10 6 /kg (range, 1.7-16.6), with 16 donors (17%) yielding less than 4 Â 10 6 /kg CD34 þ stem cells. After the first apheresis, the median number of collected CD34 þ cells was 4.9 Â 10 6 /kg (range, 1.0-16.6). Thirty-two donors (34%) underwent more than one apheresis session. No life-threatening adverse events were encountered during the mobilization and collection process. However, 11 donors (12%) experienced some adverse events during the collection process (bone pain, headache, hypotension, arrhythmia and general discomfort). Of note, no dose reduction was performed because of side effects, and none of these side effects resulted in severe morbidity or any mortality. In univariate analysis, female gender, lower weight and height, pre-G-CSF and post G-CSF Hb levels, and low CD34 þ cell counts before first apheresis, were associated with significantly lower total CD34 þ stem cells yields (o6.25 Â 10 6 /kg). In multivariate analysis, male donor gender and higher post-G-CSF CD34 þ cell counts before the first apheresis were most strongly associated with a higher (46.25 Â 10 6 /kg) total number of collected CD34 þ stem cells (OR ¼ 6.17, 95% CI (2.39-15.93), P ¼ 0.0001; and OR ¼ 3.95, 95% CI (1.53-10.19), P ¼ 0.004, respectively).
A CD34 þ cell yield o2 Â 10 6 /kg of recipient weight is usually the accepted definition of a 'poor mobilization'. However, for the purpose of this analysis and from a practical standpoint, we chose to focus on those donors with a CD34 þ stem cell yield o4 Â 10 6 /kg, which can be considered as a 'non-optimal' yield. 6 Thus, when considering the group of 16 donors with a 'non-optimal' CD34 þ stem cells yield (o4 Â 10 6 /kg), in multivariate analysis, we found that a higher post-G-CSF CD34 þ cell count before the first apheresis was the strongest parameter significantly associated with a higher total number of collected CD34 þ PBSCs (OR ¼ 6.36, 95% CI (1.68-24.15), P ¼ 0.006; Table 2 ).
Earlier studies have yielded conflicting data regarding the effect of various donor demographic, laboratory and other factors on peak donor CD34 þ mobilization responses and apheresis cell yields. 7, 8 Recently, Vasu et al. 5 identified age, 
Caucasian ethnicity and female gender to be associated with significantly lower post-G-CSF CD34 þ cell counts. In addition, they found that higher post-G-CSF CD34 þ cell counts were most strongly associated with the total amount of G-CSF received. In contrast to the study by Vasu et al., our cohort included an ethnically homogeneous Caucasian population of healthy donors who received the same dose of G-CSF (10 mg/kg/day) before mobilization. Thus, assessment of the effect of ethnicity and G-CSF dose was not possible in our series. Of note, we were not able to find a significant effect of body weight. In this analysis, we have deliberately chosen to focus our analysis on the final CD34 þ cell per recipient body weight, because we felt that this can be an 'operational' definition. Indeed, the putative confounding effects of procedural settings are eliminated by the single center nature of our study. Also, it is true that using final CD34 cell yields after repeated apheresis might mask some poor mobilized donors. However, the major objective from the practical standpoint is to achieve the targeted optimal number of CD34 þ stem cells needed for a specific patient.
Results from our study indicate that a quick assessment of risk for 'non-optimal' CD34 þ stem cells yield in healthy donors can be achieved through simple demographic and routine parameters, namely gender and post-G-CSF CD34 þ cell count. Interestingly and in accordance with other reports, 4,7 age did not seem to be a significant parameter for poor mobilization. In terms of recipients' outcome, assessment of CD34 þ cells yield could be of value in planning transplantation approaches as higher CD34 þ cell doses may be associated with improved transplant outcomes in some settings, 3 or may be associated with adverse recipient outcomes such as severe chronic GVHD. 6 From the practical standpoint, our finding that a higher post-G-CSF CD34 þ cell count before the first apheresis was the strongest parameter significantly associated with a higher total number of collected CD34 þ stem cells may be of high interest. Indeed, the advent of newer mobilizing agents such as AMD3100, a direct antagonist of CXCR4/stromal-derived factor 1 (SDF-1/CXCL12), Median platelet count after mobilization and before collection (range/ml) 219 500 (154 000-328 000) 242 500 (161 000-364 000) 0.54
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